Lynne Collins

TL;DR: It is shown here that granzyme B-deficient mice clear both allogeneic and syngeneic tumor cell lines more efficiently than do wild-type (WT) mice and Granzyme B and perforin are relevant for Treg cell-mediated suppression of tumor clearance in vivo.

TL;DR: These findings show how targeting TAMs can effectively overcome therapeutic resistance mediated by TICs and improve chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses.

TL;DR: It is demonstrated that the CD3×CD123 DART binds to both human CD3 and CD123 to mediate target-effector cell association, T-cell activation, proliferation, and receptor diversification and induces a dose-dependent killing of AML cell lines and primary AML blasts in vitro and in vivo.

TL;DR: ALT-803 represents a novel immunostimulatory drug that enhances NK-cell antilymphoma responses in vitro and in vivo, thereby supporting the clinical investigation of ALT-803 plus anti-CD20 mAbs in patients with indolent B-cell lymphoma.

TL;DR: It is shown that IFNγR(-/-) regulatory T cells (Tregs) are fully suppressive in vitro although defective in suppressor function in vivo and that WT Tregs suppress GVHD in vivo only when allogeneic Tconv produce interferon γ (IFNγ), suggesting that the IFnγR signaling pathway is the major mechanism for both T Regs and Tconv to migrate to GV HD target organs.